![]() |
|
|
Vol. 285, Issue 3, 1207-1218, June 1998
Department of Pharmacology, University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania
Fentanyl, and its structural analogs lofentanil and sufentanil, are
potent analgesics used clinically in the management of pain. However,
the high analgesic potency of these compounds is limited by the
development of tolerance after chronic use. To investigate whether
their tolerance development may be related to mu receptor
desensitization, the cloned mouse mu receptor as well as
mutant forms of the receptor were stably expressed in HEK 293 cells and
tested for their response to continuous opioid treatment. Fentanyl and
its analogs potently bound to the mu receptor and
effectively inhibited cAMP accumulation. Three-hour pretreatment of
mu receptors with fentanyl and its analogs desensitized the mu receptor by uncoupling it from adenylyl cyclase. The
fentanyl analogs caused a slight internalization of the mu
receptor as accessed by antibody binding to the epitope-tagged
mu receptor. Truncation of the mu receptor by
removal of its carboxyl terminus at Glu341 did not affect
the ability of the fentanyl analogs to bind to and activate the
mu receptor nor did it prevent the fentanyl analogs from
desensitizing the receptor. In a previous study we showed that morphine
did not desensitize the cloned mu receptor even though it is
a potent and effective agonist at the mu receptor. Mutagenesis studies revealed that morphine interacts differently with
the mu receptor to activate it than do the fentanyl analogs which may explain its lack of desensitization of the mu
receptor. These results indicate that desensitization of the
mu receptor may be a molecular basis for the development of
tolerance to fentanyl and its analogs.